CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?
CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
靶向 CD19 的嵌合抗原受体（CAR）T 细胞疗法，在治疗复发和/或难治性 B 细胞淋巴瘤、B 急性淋巴细胞白血病和多发性骨髓瘤患者方面取得了显著成果。作为一种改变既有治疗模式的新方法，该疗法从出现到获 FDA 批准的时间较短。然而，随着病例增加和时间推移，其潜在问题逐渐显现。本综述总结使用 CD19 CAR-T 治疗血液系统恶性肿瘤患者的短期和长期毒性，包括细胞因子释放综合征（CRS）、免疫效应细胞相关神经毒性综合征（ICANS），以及发生率较低但死亡率较高的继发性恶性肿瘤，例如继发性 T 细胞肿瘤和致死性 CAR 肿瘤；这些毒性可能与目前获批 CAR-T 使用的病毒载体基因修饰机制有关。综述还讨论旨在提高 CAR-T 细胞疗法安全性的潜在研究策略。
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma. As a new treatment method that has changed the existing treatment paradigm, there has been a short time from its emergence to FDA approval.
However, with the increasing number of cases and the passage of time, hidden problems have gradually been exposed.
In this review, we summarize the short- and long-term toxicity, such as secondary T-cell tumors and lethal CAR tumors, of patients with hematologic malignancies treated with CD19-CAR-T cells, including cytokine release syndrome (CRS), ICANS, and secondary malignancies with low occurrence rates but high mortality, such as secondary T cell tumors and lethal CAR tumors, which may be related to the gene modification mechanism of viral vectors currently approved for CAR-T cells.
We also discuss potential investigational strategies designed to improve the safety of CAR-T-cell therapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
